Personal information

Countries

Hungary

Activities

Collapse all

Employment (1)

University of Szeged: Szeged, HU

2017-09-03 to present (First Department of Medicine)
Employment
Source: Self-asserted source
Kata Judit Szántó

Education and qualifications (1)

University of Szeged: Szeged, HU

2011 to 2017 (Medicine)
Education
Source: Self-asserted source
Kata Judit Szántó

Works (17)

Shotgun Analysis of Gut Microbiota with Body Composition and Lipid Characteristics in Crohn’s Disease

Biomedicines
2024-09 | Journal article | Author
DOI: 10.3390/biomedicines12092100
Contributors: Péter Bacsur; Tamás Resál; Bernadett Farkas; Boldizsár Jójárt; Zoltán Gyuris; Gábor Jaksa; Lajos Pintér; Bertalan Takács; Sára Pál; Attila Gácser et al.
Source: check_circle
Multidisciplinary Digital Publishing Institute

Plasminogen Activator Inhibitor 1 Is a Novel Faecal Biomarker for Monitoring Disease Activity and Therapeutic Response in Inflammatory Bowel Diseases

Journal of Crohn's and Colitis
2024-03-01 | Journal article
DOI: 10.1093/ecco-jcc/jjad160
Contributors: Boldizsár Jójárt; Tamás Resál; Diána Kata; Tünde Molnár; Péter Bacsur; Viktória Szabó; Árpád Varga; Kata Judit Szántó; Petra Pallagi; Imre Földesi et al.
Source: check_circle
Crossref

Possible genetical predictors of efficacy and safety of budesonide-MMX in patients with mild-to-moderate ulcerative colitis, and safety comparison with methylprednisolone

Expert Opinion on Drug Safety
2023-06-03 | Journal article
DOI: 10.1080/14740338.2023.2181336
Contributors: Tamás Resál; Katalin Mangó; Péter Bacsur; Kata Szántó; Daniella Pigniczki; Csilla Keresztes; Mariann Rutka; Anita Bálint; Ágnes Milassin; Renáta Bor et al.
Source: check_circle
Crossref

Crucial steps for treatment optimization and decision making in inflammatory bowel disease management

2023-04-06 | Dissertation or Thesis
DOI: 10.14232/phd.11527
Contributors: Kata Judit Szántó
Source: check_circle
Crossref

Effects of bowel cleansing on the composition of the gut microbiota in inflammatory bowel disease patients and healthy controls

Therapeutic Advances in Gastroenterology
2023-01 | Journal article
DOI: 10.1177/17562848231174298
Contributors: Péter Bacsur; Mariann Rutka; András Asbóth; Tamás Resál; Kata Szántó; Boldizsár Jójárt; Anita Bálint; Eszter Ari; Walliyulahi Ajibola; Bálint Kintses et al.
Source: check_circle
Crossref

Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patients following COVID-19 vaccination

Therapeutic Advances in Gastroenterology
2023-01 | Journal article
DOI: 10.1177/17562848231183529
Contributors: Tamás Resál; Péter Bacsur; Miklós Horváth; Kata Szántó; Mariann Rutka; Anita Bálint; Anna Fábián; Renáta Bor; Zoltán Szepes; János Fekete et al.
Source: check_circle
Crossref

Ustekinumab is associated with superior treatment persistence but not with higher remission rates versus vedolizumab in patients with refractory Crohn’s disease: results from a multicentre cohort study

Therapeutic Advances in Gastroenterology
2022-01 | Journal article
DOI: 10.1177/17562848221144349
Contributors: Péter Bacsur; Mária Matuz; Tamás Resál; Pál Miheller; Tamás Szamosi; Eszter Schäfer; Patrícia Sarlós; Ákos Iliás; Kata Szántó; Mariann Rutka et al.
Source: check_circle
Crossref

Advances in the optimization of therapeutic drug monitoring using serum, tissue and faecal anti-tumour necrosis factor concentration in patients with inflammatory bowel disease treated with TNF-α antagonists

Expert Opinion on Biological Therapy
2021-04-03 | Journal article
DOI: 10.1080/14712598.2021.1890712
Contributors: Kata Judit Szántó; Tamara Madácsy; Diána Kata; Tamás Ferenci; Mariann Rutka; Anita Bálint; Renáta Bor; Anna Fábián; Ágnes Milassin; Boldizsár Jójárt et al.
Source: check_circle
Crossref

Does inflammatory bowel disease have different characteristics according to stage of adolescence?

Therapeutic Advances in Gastroenterology
2021-01 | Journal article
DOI: 10.1177/1756284820986670
Contributors: Kata Judit Szántó; Tamás Balázs; Dóra Mihonné Schrempf; Klaudia Farkas; Tamás Molnár
Source: check_circle
Crossref

Effect of COVID-19 pandemic on the workflow of endoscopy units: an international survey

Therapeutic Advances in Gastroenterology
2021-01 | Journal article
DOI: 10.1177/17562848211006678
Contributors: Tamás Resál; Renáta Bor; Kata Szántó; Anna Fábián; Mariann Rutka; Marco Sacco; Davide Guiseppe Ribaldone; Pauliina Molander; Stephane Nancey; Uri Kopylov et al.
Source: check_circle
Crossref

Letter: ciclosporin and vedolizumab for steroid‐refractory ulcerative colitis

Alimentary Pharmacology & Therapeutics
2020-08 | Journal article
DOI: 10.1111/apt.15896
Contributors: Tamás Resál; Daniella Pigniczki; Kata Szántó; Mariann Rutka; Klaudia Farkas; Tamas Molnar
Source: check_circle
Crossref

Letter: suicide risk among adult inflammatory bowel disease patients

Alimentary Pharmacology & Therapeutics
2020-06 | Journal article
DOI: 10.1111/apt.15708
Contributors: Anett Sánta; Kata Judit Szántó; Patrícia Sarlós; Pál Miheller; Klaudia Farkas; Tamás Molnár
Source: check_circle
Crossref

Epidemiology, mortality and prevalence of colorectal cancer in ulcerative colitis patients between 2010-2016 in Hungary – a population-based study

PLOS ONE
2020-05-14 | Journal article
DOI: 10.1371/journal.pone.0233238
Contributors: Péter Kunovszki; Valérie Pittet; Ágnes Milassin; Judit Gimesi-Országh; Péter Takács; Kata Szántó; Anita Bálint; Klaudia Farkas; András Borsi; Péter L. Lakatos et al.
Source: check_circle
Crossref

Epidemiological data and utilization patterns of anti-TNF alpha therapy in the Hungarian ulcerative colitis population between 2012-2016

Expert Opinion on Biological Therapy
2020-04-02 | Journal article
DOI: 10.1080/14712598.2020.1718097
Contributors: Péter Kunovszki; Kata Judit Szántó; Judit Gimesi-Országh; Péter Takács; András Borsi; Anita Bálint; Klaudia Farkas; Ágnes Milassin; Péter L. Lakatos; Tamás Szamosi et al.
Source: check_circle
Crossref

Serological Status of Inflammatory Bowel Disease Patients Before Starting Biological Therapy - Data From a Tertiary Centre of the Best Vaccined Country

Inflammatory Bowel Diseases
2020-03-04 | Journal article
DOI: 10.1093/ibd/izaa005
Contributors: Kata Judit Szántó; Mariann Rutka; Daniella Pigniczki; Klaudia Farkas; Katalin Burián; Gabriella Terhes; Tamás Molnár
Source: check_circle
Crossref

Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease – A nationwide Hungarian cohort study

Expert Opinion on Biological Therapy
2020-02-01 | Journal article
DOI: 10.1080/14712598.2020.1699529
Contributors: Renáta Bor; Anna Fábián; Mária Matuz; Zoltán Szepes; Klaudia Farkas; Pál Miheller; Tamás Szamosi; Áron Vincze; Mariann Rutka; Kata Szántó et al.
Source: check_circle
Crossref

New Promising Combo Therapy in Inflammatory Bowel Diseases Refractory to Anti-TNF Agents: Cyclosporine Plus Vedolizumab

Journal of Crohn's and Colitis
2018-04-27 | Journal article
DOI: 10.1093/ecco-jcc/jjx179
Contributors: Kata Szántó; Tamás Molnár; Klaudia Farkas
Source: check_circle
Crossref
How many people are using ORCID?